These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 8854254

  • 1. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L.
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [Abstract] [Full Text] [Related]

  • 2. Biochemical assessment of Paget's disease of bone.
    Shankar S, Hosking DJ.
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
    [Abstract] [Full Text] [Related]

  • 3. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease.
    Naylor KE, Jackson B, Eastell R.
    J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326
    [Abstract] [Full Text] [Related]

  • 4. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF, Margioris AN, Dretakis KE, Trovas G, Zoras U, Lyritis G, Dretakis EK, Stergiopoulos K.
    Maturitas; 2004 Mar 15; 47(3):185-93. PubMed ID: 15036488
    [Abstract] [Full Text] [Related]

  • 5. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul 15; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 6. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb 15; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

  • 7. Relationship of bone turnover to bone density and fractures.
    Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL.
    J Bone Miner Res; 1997 Jul 15; 12(7):1083-91. PubMed ID: 9200008
    [Abstract] [Full Text] [Related]

  • 8. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Muñoz-Gomez J, Rivera-Fillat F, Ballesta AM.
    J Bone Miner Res; 1995 Mar 15; 10(3):458-65. PubMed ID: 7785468
    [Abstract] [Full Text] [Related]

  • 9. Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
    Wilkinson JM, Jackson B, Eastell R.
    Calcif Tissue Int; 2003 Oct 15; 73(4):326-31. PubMed ID: 12874697
    [Abstract] [Full Text] [Related]

  • 10. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P, Tura S, Baccarani M, Cavo M.
    Eur J Haematol; 2006 May 15; 76(5):399-404. PubMed ID: 16480429
    [Abstract] [Full Text] [Related]

  • 11. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R.
    J Bone Miner Res; 1998 Jun 15; 13(6):1051-5. PubMed ID: 9626638
    [Abstract] [Full Text] [Related]

  • 12. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y, Ochi M, Tokue A.
    Hinyokika Kiyo; 2000 Dec 15; 46(12):869-72. PubMed ID: 11211802
    [Abstract] [Full Text] [Related]

  • 13. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
    Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD.
    J Bone Miner Res; 1995 Apr 15; 10(4):641-9. PubMed ID: 7610936
    [Abstract] [Full Text] [Related]

  • 14. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, Nagano A.
    Rheumatology (Oxford); 2006 Jun 15; 45(6):761-4. PubMed ID: 16436492
    [Abstract] [Full Text] [Related]

  • 15. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA.
    J Bone Miner Res; 2005 Apr 15; 20(4):588-95. PubMed ID: 15765177
    [Abstract] [Full Text] [Related]

  • 16. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
    Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wildiers J, Michel J, Leonard R, Nortier J, Mignolet F, Ford J.
    Br J Cancer; 1999 Apr 15; 80(1-2):221-8. PubMed ID: 10390000
    [Abstract] [Full Text] [Related]

  • 17. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD.
    J Bone Miner Res; 1996 Mar 15; 11(3):337-49. PubMed ID: 8852944
    [Abstract] [Full Text] [Related]

  • 18. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.
    Anticancer Res; 2005 Mar 15; 25(2B):1457-63. PubMed ID: 15865105
    [Abstract] [Full Text] [Related]

  • 19. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003 Mar 15; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 20. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD.
    Arthritis Rheum; 2002 Jan 15; 46(1):21-30. PubMed ID: 11817593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.